Principal Investigator, Velodrome. A Phase IIIb, global, multicenter,randomized, visual assessor−masked study of the efficacy, safety, and pharmacokinetics of a 36-week refill regimen for the port delivery system with ranibizumab in patients with neovascular age-related macular degeneration